Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11Michael D Jain, David B Miklos, Caron A Jacobson, et al.
Frontiers in Oncology|June 10, 2026
A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)Kedar Kirtane, Jiaxin Niu, George Blumenschein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable MelanomaJason Chesney, Igor Puzanov, Frances Collichio, et al.
Transplantation and Cellular Therapy|August 26, 2024
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
American Journal of Cancer Research|July 15, 2024
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphomaTom van Meerten, John Kuruvilla, Kevin W Song, et al.
Blood Advances|September 3, 2021
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
European Urology|December 20, 2014
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapiesNils Kroeger, Allan J Pantuck, J Connor Wells, et al.
British Journal of Haematology|September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphomaMax S Topp, Tom van Meerten, Roch Houot, et al.
American Journal of Cancer Research|September 15, 2025
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysisLori A Leslie, John H Baird, Ian W Flinn, et al.
Nature Medicine|August 29, 2022
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphomaNathalie Scholler, Regis Perbost, Frederick L Locke, et al.
Pageof 6